Header cover image

Hong Kong (HSI) Clinical Research and Equipment Industry Analysis

UpdatedMar 24, 2025
DataAggregated Company Financials
Companies9
  • 7D1.5%
  • 3M37.8%
  • 1Y73.0%
  • YTDn/a

The Clinical Research and Equipment industry is up 1.5% in the last week, with WuXi XDC Cayman up 9.9%. This means that the industry has gained 73% over the past year. As for the next few years, earnings are expected to grow by 33% per annum.

Industry Valuation and Performance

Has the Hong Kong Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 24 Mar 2025HK$217.0bHK$32.6b-HK$203,413,550.8947.8x-1066.9x6.6x
Wed, 19 Feb 2025HK$195.8bHK$35.8b-HK$1,058,538,751.4561.4x-184.9x5.5x
Fri, 17 Jan 2025HK$151.1bHK$35.6b-HK$1,062,252,938.5456.1x-142.3x4.2x
Sun, 15 Dec 2024HK$154.0bHK$35.8b-HK$1,058,466,824.6758.8x-145.5x4.3x
Tue, 12 Nov 2024HK$151.9bHK$36.1b-HK$1,055,366,091.1944x-143.9x4.2x
Thu, 10 Oct 2024HK$165.6bHK$35.9b-HK$655,249,294.0930.7x-252.7x4.6x
Sat, 07 Sep 2024HK$149.5bHK$35.9b-HK$658,597,307.6223.4x-227x4.2x
Mon, 05 Aug 2024HK$97.0bHK$33.8bHK$3.1b19.4x31x2.9x
Wed, 03 Jul 2024HK$87.7bHK$33.4bHK$3.1b17.5x28.5x2.6x
Fri, 31 May 2024HK$90.1bHK$33.6bHK$3.1b28x29.1x2.7x
Sun, 28 Apr 2024HK$108.0bHK$33.6bHK$3.1b30.6x34.9x3.2x
Tue, 26 Mar 2024HK$116.3bHK$33.2bHK$3.7b52.7x31.7x3.5x
Thu, 22 Feb 2024HK$134.2bHK$32.3bHK$3.0b56.8x45.1x4.2x
Sat, 20 Jan 2024HK$197.8bHK$32.5bHK$3.0b85.7x65.4x6.1x
Mon, 18 Dec 2023HK$212.6bHK$32.5bHK$3.0b85.2x70.5x6.5x
Wed, 15 Nov 2023HK$261.0bHK$30.1bHK$2.7b45.7x97.6x8.7x
Fri, 13 Oct 2023HK$265.0bHK$30.1bHK$2.7b47.4x99.1x8.8x
Sun, 10 Sep 2023HK$223.8bHK$30.1bHK$2.7b40.1x84.3x7.4x
Tue, 08 Aug 2023HK$235.8bHK$28.4bHK$2.7b22x86.5x8.3x
Thu, 06 Jul 2023HK$209.8bHK$28.3bHK$2.7b20.6x77.7x7.4x
Sat, 03 Jun 2023HK$235.5bHK$28.9bHK$2.8b20.9x83.6x8.1x
Mon, 01 May 2023HK$249.3bHK$29.5bHK$2.9b24.5x85.3x8.5x
Wed, 29 Mar 2023HK$251.7bHK$28.9bHK$2.5b23.3x102.7x8.7x
Fri, 24 Feb 2023HK$288.4bHK$26.3bHK$2.1b25x140.5x11x
Sun, 22 Jan 2023HK$371.2bHK$26.6bHK$2.1b27.8x174.2x14x
Tue, 20 Dec 2022HK$267.0bHK$25.9bHK$2.0b24.8x134.7x10.3x
Thu, 17 Nov 2022HK$285.7bHK$25.8bHK$1.9b26.9x146.9x11.1x
Sat, 15 Oct 2022HK$258.7bHK$25.6bHK$1.9b21.3x138.5x10.1x
Mon, 12 Sep 2022HK$343.4bHK$26.3bHK$2.0b25.7x168.7x13.1x
Wed, 10 Aug 2022HK$389.2bHK$22.3bHK$2.0b12.1x190.4x17.5x
Fri, 08 Jul 2022HK$431.2bHK$22.4bHK$2.1b14.5x207.8x19.3x
Sun, 05 Jun 2022HK$299.3bHK$22.5bHK$2.1b13.1x142x13.3x
Tue, 03 May 2022HK$312.2bHK$22.7bHK$2.2b14x145.1x13.8x
Thu, 31 Mar 2022HK$360.8bHK$23.3bHK$2.4b17.4x153.5x15.5x
Price to Earnings Ratio

153.5x


Total Market Cap: HK$360.8bTotal Earnings: HK$2.4bTotal Revenue: HK$23.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Hong Kong Clinical Research and Equipment Industry Price to Earnings3Y Average 38.6x202320242025
Current Industry PE
  • Investors are pessimistic on the Hong Kong Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 8.0x is higher than the industry's current PS ratio of 6.6x.
Past Earnings Growth
  • Total earnings for the Life Sciences Tools and Services industry have declined over the last three years, with the industry now making a loss overall.
  • Meanwhile revenues have grown 13% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Hong Kong Clinical Research and Equipment compare with similar industries?

HK Market-0.72%
Healthcare0.45%
Life Sciences1.51%
Clinical Research and Equipment1.51%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
2268 WuXi XDC CaymanHK$42.104.9%
+HK$2.3b
133.9%PE79.2x
1548 Genscript BiotechHK$12.421.0%
+HK$257.7m
-16.6%PS5.8x
1873 Viva Biotech HoldingsHK$2.002.6%
+HK$105.6m
277.4%PS2x
8225 China Health GroupHK$0.182.8%
+HK$5.0m
36.3%PS6.9x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

2269

HK$26.35

WuXi Biologics (Cayman)

7D

-0.9%

1Y

87.9%

1873

HK$2.00

Viva Biotech Holdings

7D

2.6%

1Y

277.4%

2268

HK$42.10

WuXi XDC Cayman

7D

4.9%

1Y

133.9%

6118

HK$0.84

Austar Lifesciences

7D

-2.3%

1Y

-32.3%

8225

HK$0.18

China Health Group

7D

2.8%

1Y

36.3%

1521

HK$1.06

Frontage Holdings

7D

-2.8%

1Y

-28.4%

1548

HK$12.42

Genscript Biotech

7D

1.0%

1Y

-16.6%

2576

HK$4.18

Zhejiang Taimei Medical Technology

7D

-6.9%

1Y

n/a